Tiziana Life Sciences (NASDAQ:TLSA) Shares Down 3.2% – Should You Sell?

Tiziana Life Sciences Ltd (NASDAQ:TLSA)’s stock price traded down 3.2% on Monday . The stock traded as low as $1.5103 and last traded at $1.53. 113,997 shares traded hands during trading, a decline of 30% from the average session volume of 163,390 shares. The stock had previously closed at $1.58.

Analyst Ratings Changes

Several analysts recently weighed in on the company. Wall Street Zen cut Tiziana Life Sciences from a “hold” rating to a “sell” rating in a report on Saturday, April 18th. Weiss Ratings raised Tiziana Life Sciences from a “sell (e+)” rating to a “sell (d-)” rating in a report on Wednesday, May 6th. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat, the company presently has a consensus rating of “Sell”.

Tiziana Life Sciences Trading Down 3.8%

The stock’s 50-day simple moving average is $1.31 and its 200-day simple moving average is $1.50.

Tiziana Life Sciences (NASDAQ:TLSA) last announced its earnings results on Friday, May 1st. The company reported ($0.28) earnings per share (EPS) for the quarter.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in the business. Zhang Financial LLC grew its position in shares of Tiziana Life Sciences by 12.0% during the 1st quarter. Zhang Financial LLC now owns 111,900 shares of the company’s stock worth $131,000 after purchasing an additional 12,000 shares in the last quarter. OMERS ADMINISTRATION Corp acquired a new position in shares of Tiziana Life Sciences during the 4th quarter worth approximately $59,000. Marshall Wace LLP grew its position in shares of Tiziana Life Sciences by 5.2% during the 4th quarter. Marshall Wace LLP now owns 282,017 shares of the company’s stock worth $420,000 after purchasing an additional 14,005 shares in the last quarter. HRT Financial LP acquired a new position in shares of Tiziana Life Sciences during the 4th quarter worth approximately $36,000. Finally, Goldman Sachs Group Inc. grew its position in shares of Tiziana Life Sciences by 413.9% during the 4th quarter. Goldman Sachs Group Inc. now owns 110,290 shares of the company’s stock worth $164,000 after purchasing an additional 88,830 shares in the last quarter.

Tiziana Life Sciences Company Profile

Tiziana Life Sciences plc (NASDAQ: TLSA) is a clinical-stage biotechnology company focused on the development of novel therapeutics in the fields of oncology, immunology and infectious diseases. Headquartered in London, with research and development operations in Cambridge, Massachusetts, the company advances both small-molecule inhibitors and monoclonal antibody candidates designed to modulate immune pathways and target tumor growth.

The company’s lead small?molecule program, milciclib, is an oral cyclin?dependent kinase inhibitor currently in Phase II clinical trials for hepatocellular carcinoma and certain neuroendocrine tumors.